Aclaris Therapeutics, Inc.
ACRS
$6.18
$0.162.66%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -8.33% | 37.18% | -85.94% | -24.09% | -35.76% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -8.33% | 37.18% | -85.94% | -24.09% | -35.76% |
| Cost of Revenue | 46.77% | 33.17% | -1.50% | 85.04% | 24.66% |
| Gross Profit | -55.27% | -32.67% | -83.83% | -203.09% | -45.81% |
| SG&A Expenses | 12.29% | 9.84% | 12.56% | -13.83% | 13.34% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 36.83% | 25.72% | 1.49% | 45.17% | 21.17% |
| Operating Income | -41.58% | -24.79% | -58.73% | -76.29% | -33.62% |
| Income Before Tax | -39.38% | -31.42% | 79.50% | -92.64% | -40.44% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -39.38% | -31.42% | 79.50% | -92.64% | -40.44% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -39.38% | -31.42% | 79.50% | -92.64% | -40.44% |
| EBIT | -41.58% | -24.79% | -58.73% | -76.29% | -33.62% |
| EBITDA | -41.80% | -24.97% | -59.15% | -77.64% | -33.84% |
| EPS Basic | -19.70% | -24.82% | 84.07% | -12.14% | 18.30% |
| Normalized Basic EPS | -30.85% | -27.42% | -37.60% | -24.58% | 24.95% |
| EPS Diluted | -19.70% | -24.82% | 84.07% | -12.14% | 18.30% |
| Normalized Diluted EPS | -30.85% | -27.42% | -37.60% | -24.58% | 24.95% |
| Average Basic Shares Outstanding | 16.44% | 5.25% | 28.71% | 71.78% | 71.94% |
| Average Diluted Shares Outstanding | 16.44% | 5.25% | 28.71% | 71.78% | 71.94% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |